Table 7. Characterization of Selected Compounds in Behavioral In Vivo Pharmacological Tests in Comparison to Reference Drugsa.
| compd | FST MED [mg/kg] | Vogel test MED [mg/kg] | EPM MED [mg/kg] | MK-801-induced hyperactivity MED [mg/kg] | spontaneous locomotor activity MSD [mg/kg] |
|---|---|---|---|---|---|
| 7 | >1 | >1 | >3 | ||
| 11 | 0.1 | >10 | >10 | >0.3 | |
| 16 | >3 | 1 | 1 | >10 | >3 |
| Imipramine | 10 | 10 | |||
| S-citalopram | 20 | ||||
| Quetiapine | 100 | 3 | 1 | >100 | 100 |
| Risperidone | 3 | 0.3 | 1 | ||
| Olanzapine | 3 | 1 | 3 | 1 | |
| Diazepam | 5 | 2.5 | 3 | ||
| Buspirone | 1.25 | 1.25 | |||
| Aripiprazole(64) | 3 | 1064 | >364 | >100 | 10 |
| Pimavanserin(68) | 0.1b | 0.1b |
a
Tests carried out on Wistar rats (n = 8) after intraperitoneal (i.p.) administration. MED: minimum effective dose; MSD: minimum sedative dose, blank spaces—compounds not tested in the assay.
b
Experiments performed in mice.68